Codexis, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Codexis, Inc. on December 21, 2012, reporting an event that occurred on December 18, 2012. The filing addresses the termination of a material definitive agreement with the Economic Development Board of Singapore (EDB).
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics for the current period. It specifically details historical grant revenue recognized from the terminated EDB Grant:
- Fiscal Year 2010: $3.2 million
- Fiscal Year 2011: $1.3 million
- Nine months ended September 30, 2012: $0.6 million
Future funding from the EDB under this grant is now zero.
Material Changes
The primary material change is the termination of the EDB Grant, originally dated September 28, 2009, and scheduled to expire on March 31, 2013. The termination was triggered by the Company's decision to close its Singapore facility, which was previously reported in an 8-K filed on September 6, 2012. The grant required minimum staffing and performance obligations which were no longer being met due to the facility closure.
Outlook, Risks, and Contingencies
As a direct result of the termination, the Company will not receive any further funding from the EDB. The EDB, through its indirect subsidiary Biomedical Sciences Investment Fund Pte Ltd., beneficially owns approximately 8.4% of the Company's outstanding Common Stock as of October 31, 2012. The filing references the closure of the Singapore facility, which was focused on pharmaceuticals and bioindustrial research and development, as the underlying cause for the loss of this revenue stream.
Key Facts for Investor Verification
- Confirm the total financial impact of the Singapore facility closure beyond the loss of EDB grant revenue.
- Verify the current ownership percentage of the EDB and any potential changes in shareholder composition.
- Review the September 6, 2012 Form 8-K and the Q3 2012 Form 10-Q for details on the facility closure rationale and associated costs.
- Assess the Company's revised cash flow projections given the cessation of the $0.6 million quarterly grant revenue.